

**Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration**

<b>Total number of cases reported</b>				<b>74</b>	
<b>Countries that assessed children, n</b>					
France	47	Italy	4	Mexico	2
Poland	10	India	4	United Kingdom	1
Russia	4	Portugal	2		
<b>Children</b>					
Girls / boys				29 / 44	
Age (mean ± SD)				12.2 ± 3.9 y	
<b>Psoriasis before COVID-19</b>					
Age of onset of psoriasis (mean ± SD)				6.6 ± 4.0 y	
Plaque psoriasis				48	
Nail psoriasis				38	
Psoriasis arthritis				3	
<b>COVID-19</b>					
Confirmed / suspected				64 / 10	
N° of COVID-19 / child					
1				72	
2				1	
Symptoms, yes				48	
Hospitalization				2	
Long-Covid				1	
<b>Since COVID-19 onset, the psoriasis has</b>					
Improved				0	
Worsened, with same psoriasis phenotype				8	
Worsened, phenotype changed				0	
Remained same				53	
Psoriasis de novo				5	
No information				8	
<b>Systemic medication for psoriasis at time of onset of COVID-19</b>					
Phototherapy	4	Adalimumab	6		
Methotrexate	8	Etanercept	4		
Acitretin	4	Ustekinumab	8		
Cyclosporine	1	Risankizumab	1		

**You can include children with psoriasis and COVID-19 on:**

<https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfnCx4ky8CEUILWa7veJmHb0FthGKuudaQDwbCfNQ/viewform?vc=0&c=0&w=1&flr=0>

**Website: [www.sfdermato.org/site/chi-psocov.html](http://www.sfdermato.org/site/chi-psocov.html)**